Clinical Trial Update: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update describing a combined dose-finding and cardiovascular outcomes study of CSL300 (clazakizumab) in adults with end-stage kidney disease on d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• End-stage Kidney Disease

Drugs mentioned

• Clazakizumab (clazakizumab)

Snippet

Sponsor: CSL Behring | Conditions: Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease | Phase 2, Phase 3 | Status: RECRUITING